Bio-Techne Corp (NASDAQ:TECH) Director Roger C. Lucas sold 100 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $114.30, for a total value of $11,430.00. Following the completion of the sale, the director now owns 2,070 shares in the company, valued at approximately $236,601. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bio-Techne Corp (NASDAQ TECH) opened at 117.03 on Wednesday. The company has a market cap of $4.37 billion, a price-to-earnings ratio of 56.81 and a beta of 0.79. Bio-Techne Corp has a 52 week low of $95.68 and a 52 week high of $121.94. The stock’s 50 day moving average price is $116.60 and its 200-day moving average price is $109.30.

Bio-Techne Corp (NASDAQ:TECH) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.10. Bio-Techne Corp had a net margin of 12.93% and a return on equity of 14.18%. The business had revenue of $156.60 million for the quarter, compared to analysts’ expectations of $150.25 million. During the same quarter in the previous year, the firm posted $0.92 EPS. The business’s revenue for the quarter was up 16.2% compared to the same quarter last year. On average, equities research analysts forecast that Bio-Techne Corp will post $3.99 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 18th will be issued a dividend of $0.32 per share. The ex-dividend date is Wednesday, August 16th. This represents a $1.28 dividend on an annualized basis and a yield of 1.09%. Bio-Techne Corp’s payout ratio is 65.98%.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/16/bio-techne-corp-tech-director-roger-c-lucas-sells-100-shares.html.

A number of large investors have recently modified their holdings of TECH. Israel Discount Bank of New York acquired a new stake in shares of Bio-Techne Corp during the first quarter worth about $105,000. Flinton Capital Management LLC boosted its stake in shares of Bio-Techne Corp by 10.0% in the first quarter. Flinton Capital Management LLC now owns 1,056 shares of the biotechnology company’s stock worth $107,000 after buying an additional 96 shares during the last quarter. Meadow Creek Investment Management LLC boosted its stake in shares of Bio-Techne Corp by 10.0% in the first quarter. Meadow Creek Investment Management LLC now owns 1,452 shares of the biotechnology company’s stock worth $148,000 after buying an additional 132 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Bio-Techne Corp by 12.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,456 shares of the biotechnology company’s stock worth $171,000 after buying an additional 163 shares during the last quarter. Finally, LS Investment Advisors LLC boosted its stake in shares of Bio-Techne Corp by 49.9% in the first quarter. LS Investment Advisors LLC now owns 1,712 shares of the biotechnology company’s stock worth $174,000 after buying an additional 570 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have issued reports on the company. Zacks Investment Research lowered Bio-Techne Corp from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. BidaskClub upgraded Bio-Techne Corp from a “sell” rating to a “hold” rating in a research note on Saturday. Deutsche Bank AG upped their price objective on Bio-Techne Corp from $130.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Citigroup Inc. restated a “buy” rating and issued a $125.00 price objective (up previously from $115.00) on shares of Bio-Techne Corp in a research note on Wednesday, May 3rd. Finally, TheStreet upgraded Bio-Techne Corp from a “c+” rating to a “b” rating in a research note on Tuesday, May 2nd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $125.20.

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Insider Buying and Selling by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.